CollPlant Biotechnologies (CLGN) Operating Expenses (2017 - 2026)

CollPlant Biotechnologies (CLGN) has reported Operating Expenses for 10 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 18.29% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $12.5 million (down 21.83% YoY), and the FY2025 full-year result was $13.0 million, down 19.34% from the prior year.
• Operating Expenses eased to $2.9 million in Q1 2026 per CLGN's latest filing, from $3.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $7.9 million in Q4 2022 and bottomed at $92000.0 in Q1 2022.
• Historically, Operating Expenses has averaged $3.8 million across 5 years, with a median of $3.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 97.44% in 2022, then soared 3842.39% in 2023.
• Over 5 years, Operating Expenses stood at $7.9 million in 2022, then sank by 41.99% to $4.6 million in 2023, then decreased by 10.34% to $4.1 million in 2024, then retreated by 23.02% to $3.2 million in 2025, then declined by 9.43% to $2.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $2.9 million, $3.2 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.